PAD4 were upregulated in RRMS (64), and PAD4 inhibitor exhibited improved clinical outcomes in the EAE mouse model and in the cuprizone-mediated demyelination model (65, 66). The gene discussed is PADI4; the disease is Peripheral demyelination.